Benjamin H. Lowentritt, MD, FACS, presented “Abstract Commentary: Association Between Patient-Reported Outcomes and Changes in Prostate-Specific Antigen in Patients with Advanced Prostate Cancer Treated with Apalutamide in the Spartan and Titan Studies” during the 32nd Annual International Prostate Cancer Update (IPCU32) conference on March 8, 2022, in Snowbird, Utah.
How to cite: Lowentritt, Benjamin H. “Abstract Commentary: Association Between Patient-Reported Outcomes and Changes in Prostate-Specific Antigen in Patients with Advanced Prostate Cancer Treated with Apalutamide in the Spartan and Titan Studies” March 8, 2022. Accessed Dec 2025. https://grandroundsinurology.com/abstract-commentaryassociation-between-patient-reported-outcomes-and-changes-in-prostate-specific-antigen-in-patients-with-advanced-prostate-cancer-treated-with-apalutamide-in-the-spartan-and-titan/
About the 32nd Annual International Prostate Cancer Update (IPCU32):
Presented by Program Chair E. David Crawford, MD, The International Prostate Cancer Update (IPCU), is a multi-day, CME-accredited conference focused on new developments in prostate cancer treatment, diagnosis, and prevention. IPCU 32 featured lectures, interactive discussions, panel roundtables, debates, and case reports. This conference was led by expert physicians and is designed for urologists, medical oncologists, radiation oncologists, and other healthcare professionals involved in the diagnosis and treatment of prostate cancer.
ABOUT THE AUTHOR
Benjamin H. Lowentritt, MD, FACS, is the Senior Vice President of Practice Development at the United Urology Group. His expertise includes robotic, laparoscopic, and endoscopic management of renal, bladder, and prostate cancer, as well as minimally invasive options for benign prostatic hyperplasia (BPH), kidney stones, pelvic organ prolapse, and ureteropelvic junction obstruction.
